期刊文献+

^(18)F-FDG PET/CT显像在评价不同病理亚型淋巴瘤疗效方面的价值 被引量:5

Significance of ^(18)F-FDG PET / CT imaging in evaluating curative effect of different pathologic subtypes of lymphoma
下载PDF
导出
摘要 目的探讨18F-脱氧葡萄糖(18F-FDG)PET/CT在不同病理亚型淋巴瘤疗效的评估价值。方法收集我科近4年来治疗前后均行PET/CT检查的淋巴瘤患者资料,同时根据自愿原则随机选取治疗前已行PET/CT检查的淋巴瘤患者,于治疗2~4个疗程后再次行PET/CT检查。回顾性分析并比较43例不同病理亚型淋巴瘤病灶(包括淋巴结病灶和结外灶)治疗前最大标准摄取值(SUVmax)、滞留指数(RI)和治疗后的SUVmax并进行统计学分析。所有病例随访至少3个月。结果治疗前霍奇金淋巴瘤(HL)与非霍奇金淋巴瘤(NHL)的病灶间平均SUVmax比较及RI比较差异无统计学意义。治疗前不同病理亚型的NHL淋巴瘤病灶平均SUVmax及RI与NHL的侵袭性呈正相关性,与淋巴瘤的分期无明显相关;治疗后43例患者达到完全缓解23例,部分缓解16例,疾病稳定状态1例,复发或进展3例。治疗前后淋巴瘤病灶的SUVmax差异有统计学意义(P<0.01)。结论 18F-FDG PET/CT显像对淋巴瘤患者治疗前后病灶平均SUVmax及RI的比较分析能有效评价疗效、判断预后,并为进一步治疗方案制定提供帮助和指导。 Objective The purpose of this study was to identify the roles of 18 F-FDG PET/CT imaging in evaluating the therapeutic efficacy of lymphoma with different pathologic subtypes. Methods Patients with lymphoma who had received PET/CT check in pre-therapy and post-therapy for nearly four years were recruited in this study. Patients with lymphoma who had received such checks before treatment were also randomly selected voluntarily, and another PET/CT imaging was performed on them after 2~4 courses of treatment. Finally, the pre-therapy and post-treat-ment maximumstandardized uptake value ( SUVmax) or retention index ( RI) of 43 lymphoma lesions with different subtypes ( including the lymph gland lesion and the extranodal lesion) were analyzed, comparing both retrospective-ly and statistically. In addition, all patients received a follow-up at least 3 months. Results By comparison, there was no significant difference in the RI and the average SUVmax between Hodgkin lymphoma ( HL ) lesions and Non-Hodgkin lymphoma ( NHL) lesions before treatment. Besides, the RI and the average SUVmax of NHL lym-phoma lesions with different subtypes had a positive relation to NHL invasiveness before treatment. However, no obvious relation existed between the RI and the average SUVmax of NHL lymphoma lesions and the periodization of lymphoma. After treatment, 23 of the 43 patients showed complete remission, 16 patients showed partial remission, 1 patient had stable disease, and 3 had relapsed disease/progressive disease. In a word, the SUVmax differences of lymphoma lesions before and after the treatment had significant statistical significance ( P〈0. 01 ) . Conclusion With regard to the comparative analysis of average SUVmax and RI before and after lymphoma lesion treatment, 18 F-FDG PET/CT imaging can evaluate the curative effects and prognosticate diseases effectively,and provide assis-tance and guidance for the formulation of a further therapeutic schedule as well.
出处 《安徽医科大学学报》 CAS 北大核心 2015年第2期194-197,共4页 Acta Universitatis Medicinalis Anhui
基金 安徽省科技厅第三批年度重点项目(编号:1301043021)
关键词 淋巴瘤 18 F-FDG PET/CT SUVMAX 滞留指数 疗效评价 lymphoma 18 F-FDG PET/CT SUVmax retention index curative effect evaluation
  • 相关文献

参考文献4

二级参考文献23

  • 1杜欣,李群华,翁建宇,陆泽生,谢蓉,唐安戊,林伟,黄梓伦.^(18)F-氟代脱氧葡萄糖-正电子发射断层扫描技术在恶性淋巴瘤诊治中的临床研究[J].肿瘤防治研究,2004,31(6):365-366. 被引量:4
  • 2管樑 ,Rebecca Elstrom ,Zhuang Hong-ming ,Stephen J.Schuster ,朱承谟 ,Abass Alavi .^(18)F-FDG PET显像对不同亚型淋巴瘤的诊断价值[J].中华核医学杂志,2004,24(4):207-209. 被引量:9
  • 3纪小龙.丙型肝炎与胃肠道淋巴瘤关系密切[J].新消化病学杂志,1997,5(5):279-279. 被引量:1
  • 4石美鑫.实用外科学(第1版)[M].北京:人民卫生出版社,1992.782-783.
  • 5Thill R, Neuerburg J, Fabry U, et al. Comparison of findings with ^18F-FDG PET and CT in pretherapeutic staging of malignant lymphoma [J]. Nukearmedizin, 1997,36(7) :234-239.
  • 6FreudenbergL S, Antoch G, Schutt P, et al. FDG PET-CT in restaging of patients with lymphoma [J]. Eur J Nucl Med Mol Imaging, 2004,31 (3) : 325-329.
  • 7Allen-Auerbach M, Quon A, Weber WA, et al. Comparison between 2-deoxy-2- [ ^18F] fluoro-D-glucose positron emission tomography and positron emission tomography computed tomography hardware fusion for staging of patients with lymphoma [J]. Mol Imaging Biol, 2004,6(6):411-416.
  • 8Chenson BD, Pfistner B, Juweid ME, et al. Revised response criterian for malignant lymphoma [J]. J Clin Oncol, 2007,25 (5):1-8.
  • 9Yoshioka T, Takahashi H, Oikawa H, et al. Accumulation of 2-deoxy-2 [^18F] fluoro-D-glucose in human cancers heterotrasplanted in nude mice: comparison between histology and glycolytic status [ J ]. Nucl Med, 1994,35 ( 1 ) : 97-103.
  • 10Hoffmann M, Kletter K, Diemling M, et al . Positron emission tomography with 18F-fluoro-deoxy-D-glucose (^18F-FDG) does not visualize extranodal B2 cell lymphoma of the mucosa- associated lymphoid tissue (MALT)-type [J]. Ann Oncol, 1999,10(10) : 1185-1189.

共引文献27

同被引文献54

  • 1李红,韩艳秋,王雪梅.PET/CT在淋巴瘤中的应用进展[J].中华临床医师杂志(电子版),2012,6(20):141-143. 被引量:6
  • 2单曙光,李向培,厉小梅,汪国生,钱龙.45例皮肌炎临床分析[J].安徽医学,2006,27(2):108-109. 被引量:1
  • 3张国旭,陈兰兰.淋巴瘤检查中PETCT临床应用及表现[J].中外健康 文摘,2012,(40):199 -200.
  • 4Raizer J J, Rademaker A, Evens AM, et al. Pemetrexed in the treatment o{ relapsed/refractory primary central nerv ous system lymphoma[J]. Cancer, 2012,118 (15) : 3743- 3748.
  • 5Pakos EE, Fotopoulos AD, Ioannidis JP. 18 FFDG PET for evaluation of bone marrow infiltration in staging o{ lymphoma: a meta-analysis[J]. J Nucl Med, 2005,46 ( 6 ) .. 958-963.
  • 6Wirth A,Foo M,Seymour JF,et al. Impact of 18F fluoro deoxygluc0se positron emission tomography on staging and management o{ early-stage follicular non hodgkin lymphoma[J]. Int J Radiat Oncol Biol Phys, 2008,71 (1) : 213 219.
  • 7Chavdarova LI,Tzonevska AD,Piperkova EN. Discrepancies and prioritiesin staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI[J]. Hell J Nucl Med,2013 ,16(3):223-229.
  • 8萨日.(18)F-FDGPET-CT在淋巴瘤疗效评价中的临床价值[D].长春:吉林大学,2012.
  • 9Sureshbabu W,Mawlawi 0. PET/CT imaging artifacts[J]. J Nucl Med Technol,2005,33(3):156-161.
  • 10Kamel AI,Ali TF,Tawab MA. Potential impact of PET/CT on the initialstaging of lymphoma[J]. Egyptian J Rad Nuclear Medicine,2013,44(2):331-338.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部